CING

Rating buyTentativeAI Memo

Cingulate

As of 2026-04-10/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-10 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech buy thesis remains too speculative for a standard-conviction report

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Private placement proceeds and runway extension • 2026-02-17

Expected move: +119%

Biggest risk

Failure to convert the patent allowance into issued protection, delays or scale-up problems with manufacturing, or clinical/commercial setbacks that force additional dilutive financings could push valuation below current levels.

Invalidation

Break below $4 or thesis failure.

What would change my mind?

Patent issuance plus successful manufacturing scale-up and favorable commercial data/partnerships drive re-rating toward higher analyst targets; scenario assumes commercial optionality materializes and interest from specialty pharma/partners.

Research note

Recommendation

buy

Confidence

medium

As of

2026-04-10

Base target

$10

p=50%

Bull target

$17

p=30%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

U.S.
patent allowance and expected issuance for CTx-1301 (PTR platform)
Scale-up / manufacturing partnership execution for CTx-1301 commercialization

BearKey bullets

Clinical/regulatory setbacks for CTx-1301
Manufacturing scale-up delays or quality issues
Need for additional dilutive financing if burn exceeds plan

WatchKey bullets

Private placement proceeds and runway extension

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $10 (p=50%)

Bull/Bear spread: +292% / -8%

Vs latest close: Bull +292% · Base +119% · Bear -8%

Scenario probabilities

Bull Target: $17 (p=30%)Base Target: $10 (p=50%)Bear Target: $4 (p=20%)

Commentary

Recent corporate communications emphasize IP progress (Notice of Allowance) and commercialization preparations, producing a constructive operational tone among investors [#PR-2026-03-18]. The closing of a $12M private placement reduced near-term financing anxiety, supporting modest positive sentiment [#PR-undated]. An 8-K filing confirmed a March 27, 2026 report date, signalling routine disclosure activity without surprise governance items [#8-K-2026-04-02].

As of 2026-04-10 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

U.S. patent allowance and expected issuance for CTx-1301 (PTR platform)
Scale-up / manufacturing partnership execution for CTx-1301 commercialization

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-04-10Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$9.50

Range (USD)

$5.85 - $17.00

Count

Query: Cingulate Inc Common (CING) analyst consensus price target high low average

Cingulate (CING) Stock Forecast & Price Target - Investing.com
Search result #1
According to projections from 5 analysts, the average 12-month price target for Cingulate is 28.702 USD, with a high estimate of 55 USD and a low estimate ...
Extracted: $28.70, $55.00Open source
Cingulate Inc.: Target Price Consensus and Analysts ...
Search result #2
Analysts' Consensus ; Mean consensus. BUY ; Number of Analysts. 3 ; Last Close Price. 5.850USD ; Average target price. 28.70USD ; Spread / Average Target. +390.63%.
Extracted: $5.85, $28.70Open source
CING | Cingulate Inc. Common Stock Analyst Forecasts
Search result #6
The median price target is a 183.33% change from the last price of $6.00. The highest analyst price target is $58.00, and the lowest forecast is $14.00. * ...
Extracted: $6.00, $58.00, $14.00Open source
Cingulate (CING) Stock Forecast: Analyst Ratings, Predictions ...
Search result #7
Financial analysts have set a price target of $34.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated ...
Extracted: $34.50Open source
CING Stock Quote Price and Forecast - CNN
Search result #9
Cingulate, Inc. ; Price Momentum. CING is trading in the middle ; Price change. The price of CING shares has increased $0.13 ; Opened at $5.87. The stock opened ...
Extracted: $5.87Open source
Cingulate Inc. (CING) Stock Price, News, Quote & History
Search result #5
Cingulate price target lowered to $16 from $17 at Roth Capital ... Price Target 58 -> 55. View More. Statistics: CING. View More. Valuation ...
Extracted: $16.00, $17.00Open source2 days ago

Scenarios

Bull Target (Scenario probability)

$17 / p=30% prob

Base Target (Scenario probability)

$10 / p=50% prob

Bear Target (Scenario probability)

$4 / p=20% prob

Price $4 as of 2026-05-28

Nearest Scenario: Bear (∆ 8%)

Targets vs latest close: Bull +292% · Base +119% · Bear -8%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-02-17
Private placement proceeds and runway extension
Company closed a $12.0M private placement priced at-the-market in Feb 2026; this financing reduces near-term dilution risk and extends runway to support late-stage development/commercial activities [#PR-undated][#PR-2026-03-18].
Prob 90.00% • Move 8.00% • Priced-in 80.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

U.S. patent allowance and expected issuance for CTx-1301 (PTR platform)
2026-12-31
Company disclosed a Notice of Allowance for a U.S. patent covering CTx-1301 formulation/methods that, upon issuance, is expected to provide protection through May 2042; patent issuance strengthens IP around the PTR platform and supports commercialization optionality [#PR-2026-03-18].
Prob 70% • Move 35% • Priced-in 25%
Scale-up / manufacturing partnership execution for CTx-1301 commercialization
2027-04-10
Management announced an exclusive manufacturing partnership (Bend Bio Sciences) to support future commercialization of the next-generation ADHD treatment; successful scale-up and initial commercial supply agreements would be a material commercial de-risking event [#PR-undated][#PR-2026-03-18].
Prob 55% • Move 40% • Priced-in 15%

Risks

Clinical/regulatory setbacks for CTx-1301
Manufacturing scale-up delays or quality issues
Need for additional dilutive financing if burn exceeds plan
Patent not issued or narrower-than-expected claims

Peers

Symbol	Summary
LTRN	Small-cap oncology/therapeutics developer with similar market cap and typical program-stage volatility—useful as an event-driven biotech comparator.
DMRA	Early-stage biotech with comparable market cap and clinical-readout sensitivity; operational cadence mirrors Cingulate's stage-specific catalysts.
RNTX	Small-cap clinical-stage therapeutics peer; comparable financing/runway dynamics and commercial-partnership relevance.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Cingulate Inc Common (CING) analyst consensus price target high low average
Analysis date: 2026-04-10

AI Stock Memo: CING - Cingulate - RankAlpha